Eric Padron, MD

BOARD CERTIFICATION:
          •  Internal Medicine

FELLOWSHIP:
          •  Moffitt Cancer Center - Hematology/Oncology

RESIDENCY:
          •  University of Florida Shands Hospital

MEDICAL SCHOOL:
          •  University of Florida - MD

• Padron E, Abdel-Wahab O. Importance of Genetics in the Clinical Management of Chronic Myelomonocytic Leukemia. J Clin Oncol. 2013 May. Pubmedid: 23690427.


• Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr. Pubmedid: 23605934.


• Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Apr. Pubmedid: 23632888.


• Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.


• Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct;19(4 Suppl):4-15. Pubmedid: 23042420.


• Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.


• Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.


• Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb;3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.


• Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. Curr Treat Options Oncol. 2011 Dec;12(4):354-368. Pubmedid: 21964863.


• Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb;4(1):61-69. Pubmedid: 21322779.


• Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011;(62):71.

Generally, my clinical interests are the care and treatment of patients with adult myeloid malignancies including MDS, AML and Myeloproliferative Neoplasms (MPNs) with a specific interest in the Myeloproliferative/Myelodysplastic (MDS/MPN) syndromes of which CMML is a member.